Zyprexa Intramuscular — Class II drug recall D-0720-2021
Terminated recall by Eli Lilly & Company, reported 2021-08-18, distributed in IN, MS, OH. cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug pro
| Recall number | D-0720-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Eli Lilly & Company, Indianapolis, IN, United States |
| Recall initiated | 2021-06-29 |
| Classified | 2021-08-11 |
| Reported by FDA | 2021-08-18 |
| Terminated | 2023-07-29 |
| Distributed | IN, MS, OH |
| Quantity | 36,540 vials |
| Reason classes | cgmp |
| NDC | 00002-7597-01 |
| Lot numbers | 197 |
Product
Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01
Reason for recall
cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0720-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.